Boston Scientific reported net sales of $3.389 billion for the first quarter of 2023, representing a 12.0% increase on a reported basis. GAAP net income attributable to Boston Scientific common stockholders was $300 million, or $0.21 per share, while adjusted EPS reached $0.47.
Net sales increased by 12.0% on a reported basis, 14.9% on an operational basis, and 14.0% on an organic basis compared to the prior year period.
GAAP net income attributable to Boston Scientific common stockholders was reported at $0.21 per share, while adjusted EPS was $0.47 per share.
MedSurg segment net sales grew by 11.0% reported, 13.4% operational and organic.
Cardiovascular segment net sales increased by 12.7% reported, 15.9% operational and 14.4% organic.
The company estimates net sales growth for the full year 2023 to be approximately 8.5 to 10.5 percent on a reported basis, and approximately 8 to 10 percent on an organic basis. The company estimates EPS on a GAAP basis in a range of $0.93 to $1.02 and estimates adjusted EPS of $1.90 to $1.96.
Visualization of income flow from segment revenue to net income